Broadspectrum 2-amino-benzothiazole sulfonamide hiv protease inhibitors
CA 2492832 C · Owner: Tibotec Pharmaceuticals Ltd. · Inventors: Surleraux, Dominique Louis Nestor Ghislain; Wigerinck, Piet Tom Bert Paul; Getman, Daniel P.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to the use of 2-amino-benzothiazoles having the , formula (I) wherein R1 is hexahydrofuro2,3-bfuranyl tetrahydrofuranyl, oxazolyl, thiazolyl pyridinyl, or phenyl optionally substituted with one or more substituents independently selected from C1-6-alkyl hydroxy, amino, halogen, aminoC1-4-alkyl and mono-or di(C1-4alkyl)amino; R2 is hydrogen or C1- 6alkyl; L is a direct bond, -0-, C1-6alkanediyl-O- or -O-C1-6alkanediyl; R3 is phenylC1-4alkyl; R4 is C1-6alkyl; R5 is hydrogen or C1-6alkyl; R6 is hydrogen or C1-6alkyl; in the manufacture of a medicament useful for inhibiting mutant HIV protease in a mammal infected with said mutant HIV protease. It also relates …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 4, 2003 and granted May 22, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 4, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 4, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.